We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 16 for:    zerenex

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D (05D)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02492620
First Posted: July 8, 2015
Last Update Posted: August 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Keryx Biopharmaceuticals
Information provided by (Responsible Party):
Denver Nephrologists, P.C.
  Purpose
It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy.

Condition Intervention Phase
Chronic Kidney Disease Hyperphosphatemia Iron Deficiency Anemia Renal Insufficiency Drug: Ferric Citrate Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Two-Arm, Open-Label, Standard of Care Control Evaluation of Ferric Citrate for the Transition From Chronic Kidney Disease Stage 4/5 to Chronic Kidney Stage 5D

Resource links provided by NLM:


Further study details as provided by Denver Nephrologists, P.C.:

Primary Outcome Measures:
  • Serum phosphate value prior to starting renal replacement therapy [ Time Frame: baseline ]

Secondary Outcome Measures:
  • Serum hemoglobin prior to starting renal replacement therapy [ Time Frame: baseline ]
  • Serum transferrin saturation prior to starting renal replacement therapy [ Time Frame: baseline ]
  • Serum fibroblast growth factor 23 prior to starting renal replacement therapy [ Time Frame: baseline ]

Other Outcome Measures:
  • Cumulative dose of erythropoietin analog [ Time Frame: Baseline visit to 90 days after starting renal replacement therapy ]
    Total dose of ESA received in units from baseline visit to 90 days post renal replacement

  • Cumulative dose of intravenous iron [ Time Frame: Baseline visit to 90 days after starting renal replacement therapy ]
    Total dose of intravenous iron received in units from baseline visit to 90 days post renal replacement


Enrollment: 200
Study Start Date: March 2015
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ferric Citrate
Ferric citrate (FC) will be supplied as tablets containing 210mg of ferric iron (as 1g ferric citrate) to those subjects randomized to FC. These participants will be initiated on study drug with a fixed dose of FC beginning with 2 tablet per meal.
Drug: Ferric Citrate
Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
Other Name: Auryxia
No Intervention: Standard of Care (SOC)
Participants may receive open-label, non-FC phosphate binders at the discretion of their treating physician. During the Dialysis Period, dose of phosphate binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.

Detailed Description:

This is an up to 50 week, phase 3, clinical trial in patients with estimated glomerular filtration rate (eGFR) ≤ 20 ml/min/1.73m2. It will be comprised of an up to 36-week non-dialysis period (NDP), or until such time as subjects require renal replacement therapy (RRT) with dialysis when they will immediately roll into a 12-week dialysis period (DP). The study will consist of up to 16 clinic visits over a maximum period of 50 weeks. There will be a screening period of up to 14 days after which subjects will be randomized into the NDP in a 2:1 ratio to receive either FC (n=150) or SOC (n=75). Each eligible participant will be randomized to either fixed dose open-label ferric citrate (FC) or standard of care (SOC) treatment. Participants randomized to SOC will receive care directed by their primary nephrologist throughout the study duration with the only restriction being that they cannot receive treatment with FC during the NDP or DP. Participants randomized to FC will receive it throughout the study duration.

220 participants were screened to randomize 200 subjects 2:1 (FC:SOC) into the NDP. It is anticipated that 35-45% of participants will reach the dialysis period (DP) during the 36 week follow up. Participants who initiate RRT with dialysis will enter the Dialysis Period (DP) during which those participants previously assigned to ferric citrate will continue to receive open-label ferric citrate and those previously assigned to SOC will receive open-label, non-FC phosphate binders at the discretion of their treating physician. During this period all participants will be treated to standard of care guidelines which suggest that if serum phosphate is above the upper limit of normal (4.5 mg/dL), it should be reduced. During the DP, dose of P binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.

Only participants that begin permanent RRT with dialysis will be eligible to enter the 12 week DP. Participants that do not begin RRT after 9 months participation in the NDP will be deemed to have reach the end of study and have end of study procedures performed.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age >18 years at screening visit
  2. Serum phosphate > or equal to 3.0 mg/dL obtained at screening
  3. CKD with eGFR < or equal to 20 mL/min obtained at screening*
  4. Hemoglobin (Hgb) >8.0 g/dL obtained at screening
  5. TSAT <55% obtained at screening
  6. Females of child bearing potential with negative serum pregnancy test obtained at screening
  7. Willing and able to give written informed consent
  8. Anticipated to have > or equal to 8 weeks prior to need for initiating RRT in the opinion of the investigator

Exclusion Criteria:

  1. Liver enzymes (ALT/AST) >X3 times upper limit of normal at screening
  2. Use of IV iron, blood transfusions or ESA agents within 2 weeks prior to the screening visit and prior to the Day 1 visit.
  3. Evidence of acute kidney injury (i.e., no CKD) or planned need for RRT within 12 weeks of screening
  4. Scheduled kidney transplant within 24 weeks of screening
  5. Contra-indication to ferric citrate: iron overload syndrome, allergic reaction or known intolerance to ferric citrate
  6. Clinically significant medical condition felt to interfere with tolerance of oral medication
  7. Life expectancy < 6 months or confirmed conviction that subject does NOT want to initiate RRT despite a decline in kidney function
  8. Active drug or alcohol dependence or abuse (excluding tobacco use or marijuana use) within the 12 months prior to screening (in the opinion of the PI)
  9. Psychiatric disorder that interferes with the subject's ability to comply with the study protocol in the opinion of the PI
  10. Any other medical condition that, in the opinion of the PI, renders the subject unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the subject
  11. Inability to cooperate with study personnel or study procedures
  12. Females who are pregnant or breastfeeding
  13. Receiving or has received any investigational drug with in the past 30 days prior to the Day 1 visit
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02492620


Locations
United States, Colorado
Denver Nephrologists, P.C.
Denver, Colorado, United States, 80230
Sponsors and Collaborators
Denver Nephrologists, P.C.
Keryx Biopharmaceuticals
Investigators
Principal Investigator: Geoffrey A Block, MD Denver Nephrologists, P.C.
  More Information

Responsible Party: Denver Nephrologists, P.C.
ClinicalTrials.gov Identifier: NCT02492620     History of Changes
Other Study ID Numbers: 05D
First Submitted: June 30, 2015
First Posted: July 8, 2015
Last Update Posted: August 21, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Denver Nephrologists, P.C.:
ferric citrate
phosphate
kidney

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Anemia, Iron-Deficiency
Renal Insufficiency
Hyperphosphatemia
Urologic Diseases
Anemia, Hypochromic
Anemia
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Phosphorus Metabolism Disorders
Citric Acid
Ferric Compounds
Anticoagulants
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Hematinics